Sio Gene Therapies | 15-12G: Notice of termination of registration of a class of securities under Section 12(g) (and amendment thereto)
Sio Gene Therapies | EFFECT: Others
Sio Gene Therapies | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Sio Gene Therapies | S-8 POS: S-8 POS
Sio Gene Therapies | 25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)
Sio Gene Therapies | 25: Notification of the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)
Sio Gene Therapies | 8-K: Current report
Sio Gene Therapies | DEFA14A: Others
Sio Gene Therapies | 8-K: Current report
Sio Gene Therapies | DEFM14A: Definitive proxy statement relating to merger or acquisition
Sio Gene Therapies | DEFA14A: Others
Sio Gene Therapies | 8-K: Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
Sio Gene Therapies | 10-Q: Q3 2023 Earnings Report
Sio Gene Therapies | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Suvretta Capital Management, LLC(0%),Averill Master Fund, Ltd.(0%), etc.
Sio Gene Therapies | SC 13G: Statement of acquisition of beneficial ownership by individuals-Rubric Capital Management LP(9.46%),David Rosen(9.46%)
Sio Gene Therapies | PREM14A: Preliminary proxy statements relating to merger or acquisition
Sio Gene Therapies | DEFA14A: Others
Sio Gene Therapies | 8-K: Current report
Sio Gene Therapies | 8-K: Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results
Sio Gene Therapies | 10-Q: Q2 2023 Earnings Report
No Data